Am J Transplant, Volume 22, Suppl 3 Archives - Page 158 of 190 - ATC Abstracts

2022 American Transplant Congress
Racial and Immunologic Disparities Impact Access to Repeat Kidney Transplantation Among Patients with Previous Failed Kidney Allograft
B. P. Lovasik¹, R. Zhang¹, R. Lynch¹, R. Patzer¹, A. Adams²
¹Emory University, Atlanta, GA, ²University of Minnesota, Minneapolis, MN
*Purpose: The number of patients with a failed kidney transplant who are being considered for retransplantation is increasing steadily. However, disparities in access to repeat…
2022 American Transplant Congress
The Impact of Tacrolimus Trough Variability on Acute Rejection Following Lung Transplantation
K. Evans¹, K. Beermann¹, H. Lee², M. Harris¹, C. W. Frankel³, H. Berry¹, H. Ali³
¹Pharmacy, Duke Health, Durham, NC, ²Biostatistics and Bioinformatics, Duke University, Durham, NC, ³Pulmonary, Allergy, and Critical Care, Duke Health, Durham, NC
*Purpose: This study aimed to evaluate the association of tacrolimus coefficient of variation (CV) with biopsy-proven acute cellular rejection in the first year following lung…
2022 American Transplant Congress
Evolution of Cellular and Humoral Immunity During and After a Three Doses-Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients
D. Cucchiari¹, N. Egri¹, J. Casals-Urquiza², J. Del Risco-Zevallos¹, D. Rodríguez-Espinosa³, E. Montagud-Marrahi², J. Rovira⁴, M. Ramirez-Bajo⁵, E. Banón-Maneus⁵, P. Ventura-Aguiar², M. Pascal¹, I. Revuelta⁶, B. Bayès², F. Diekmann²
¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Spain, ³Nephrology and Renal Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Laboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain, ⁵IDIBAPS, Barcelona, Spain, ⁶Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain
*Purpose: Seroconversion after a 2 doses of mRNA COVID-19 vaccine in kidney transplant recipients (KTR) ranges between 30 and 50% in different series. We previously…
2022 American Transplant Congress
Donor-Derived Cell-Free DNA Across the Spectrum of Solid Organ Transplantation
S. R. Potter¹, J. Miles², K. Qu², R. Woodward², S. Dholakia²
¹Baylor Scott & White Health, Temple, TX, ²CareDx, Inc, Brisbane, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a robust and clinically useful analyte initially validated for kidney allograft surveillance. Emerging data support the utility of dd-cfDNA…
2022 American Transplant Congress
Everolimus Alleviates Renal Allograft Interstitial Fibrosis by Inhibiting Epithelial to Mesenchymal Transition Not Only via Inducing Autophagy but Also via Stabilizing iκB-α
Z. Gui¹, W. Zijie², M. Zheng³, M. Gu¹, R. Tan³
¹Department of Urology, The Second Affiliated Hospital with Nanjing Medical University, Nanjing, China, ²Jiangsu Province Hospital, Nanjing, China, ³Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
*Purpose: Chronic allograft dysfunction (CAD) is the major cause of late graft loss in long-term renal transplantation. In our previous study, we found Epithelial-mesenchymal transition…
2022 American Transplant Congress
Impact of a Transplant Pharmacy Collaborative Practice Agreement Implementation on an Institutional Medication Assistance Program Funding Utilization
A. D. Kataria¹, T. Sam¹, N. Wilson¹, A. Lee², L. Cole², D. Francis³, L. Zuniga³, B. Stein³, R. Goldstein³
¹Pharmacy, Baylor University Medical Center, Dallas, TX, ²Baylor Health Enterprise, Dallas, TX, ³Transplant, Baylor University Medical Center, Dallas, TX
*Purpose: Post-transplant medication cost can pose a significant barrier for patient adherence and graft outcomes. Strategic selection of medication agent is often challenging and requires…
2022 American Transplant Congress
Histologic Borderline Reflects Molecular Injury Not Rejection: Results from the Trifecta Study
P. F. Halloran¹, K. S. Madill-Thomsen¹, Z. Demko², A. Prewett², P. Billings², P. Gauthier², .. and the Trifecta Investigators³
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Natera Inc., San Carlos, CA, ³., ., AB, Canada
*Purpose: In the Trifecta study (NCT04239703), we recently compared indication biopsy diagnoses (MMDx and histology) and plasma %dd-cfDNA levels for indication biopsies (JASN in press…
2022 American Transplant Congress
Wide Spectrum of Molecular Injury Highlights Heterogeneity of Banff Tubulitis and Interstitial Inflammation Lesions
M. J. Ellis¹, T. Maw², E. Huang³, E. Stites⁴, F. Shihab⁵, D. C. Brennan⁶, G. Shekhtman⁷, N. Agrawal⁷, J. Zeng⁷, S. Kung⁸
¹Duke University, Durham, NC, ²University of Southern California, Los Angeles, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of Colorado, Aurora, CO, ⁵University of Utah, Salt Lake City, UT, ⁶Johns Hopkins School of Medicine, Baltimore, MD, ⁷CareDx, Brisbane, CA, ⁸University of California, San Francisco, San Francisco, CA
*Purpose: The pathological definition and clinical significance of borderline T cell-mediated rejection (BL-TCMR) remains an area of active debate, leading to inconsistencies in therapeutic strategy.…
2022 American Transplant Congress
Correlation of Donor-Derived Cell-Free DNA with Histology and Molecular Diagnoses of T-cell Mediated Rejection in Kidney Transplant Biopsies
D. Kumar¹, I. Moinuddin¹, L. Kamal¹, M. Shinbashi¹, N. Raju¹, R. Minniti¹, F. Moran¹, P. Halloran², G. Gupta¹
¹Virginia Commonwealth University, Richmond, VA, ²University of Alberta, Edmonton, AB, Canada
*Purpose: We have reported the correlation of donor-derived cell-free DNA (dd-cfDNA) with histologic and molecular diagnosis (MMDx) of kidney transplant biopsies (Gupta et al, Transplantation…
2022 American Transplant Congress
Conversion from Immediate to Extended-Release Tacrolimus (LCP-Tac) Six Months After Renal Transplantation Optimizes Safety and Efficacy
S. P. Patel, F. Bartlett, T. Sprague, J. Newman, E. Andrade, N. Rao, N. Patel, D. Dubay, V. Rohan, M. Casey, D. Taber
MUSC Health, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for prevention of rejection in kidney transplant recipients (KTRs) that may have less variability and…